<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The most common site of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is the liver </plain></SENT>
<SENT sid="1" pm="."><plain>Hepatic resection is considered to be the treatment of choice for <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>; however, hepatic resection can be performed in only 20 or 25Â % of <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>Recurrence develops in the remnant liver or other organs after hepatic resection in over half of <z:hpo ids='HP_0000001'>all</z:hpo> patients with liver-only <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Hepatic arterial infusion (HAI) chemotherapy can provide relatively high concentrations of drugs to microscopic or macroscopic <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in the liver, with less toxicity than systemic administration </plain></SENT>
<SENT sid="4" pm="."><plain>Meta-analyses have shown HAI chemotherapy to have a significantly higher response rate than systemic chemotherapy and its effect on extrahepatic <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> is negligible </plain></SENT>
<SENT sid="5" pm="."><plain>HAI chemotherapy provides much better local control of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> than systemic chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>However, well-controlled studies are needed to elucidate the optimal treatment strategies for neoadjuvant and postoperative adjuvant chemotherapy that optimally combine HAI chemotherapy, molecular targeted agents, and systemic chemotherapy such as FOLFOX or FOLFIRI </plain></SENT>
</text></document>